CEBP Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ginolhac, S. M.
Right arrow Articles by Sinilnikova, O. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ginolhac, S. M.
Right arrow Articles by Sinilnikova, O. M.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 90-95, February 2003
© 2003 American Association for Cancer Research

BRCA1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA1 Germ-Line Mutations1

Sophie M. Ginolhac, Sophie Gad, Marilys Corbex, Brigitte Bressac-de-Paillerets, Agnès Chompret, Yves-Jean Bignon, Jean-Philippe Peyrat, Joelle Fournier, Christine Lasset, Sophie Giraud, Danièle Muller, Jean-Pierre Fricker, Agnès Hardouin, Pascaline Berthet, Christine Maugard, Catherine Nogues, Rosette Lidereau, Michel Longy, Sylviane Olschwang, Christine Toulas, Rosine Guimbaud, Drakoulis Yannoukakos, Csilla Szabo, Francine Durocher, Anne-Marie Moisan, Jacques Simard, Sylvie Mazoyer, Henry T. Lynch, David Goldgar, Dominique Stoppa-Lyonnet, Gilbert M. Lenoir2 and Olga M. Sinilnikova3

Centre National de la Recherche Scientifique, UMR 5641, Lyon, France [S. M. G., S. M.]; Centre International de Recherche sur le Cancer, Lyon, France [S. M. G., M. C., C. S., D. G., G. M. L., O. M. S.]; Institut National de la, France Santé et de la Recherche Médicale (INSERM) U509, Service de Génétique Oncologique, Institut Curie, Paris, France [S. Ga., D. S-L.]; Institut Gustave Roussy, Villejuif, France [B. B-d-P., A. C.]; Centre Jean Perrin, Clermont-Ferrand, France [Y-J. B.]; Centre Oscar Lambret, Lille, France [J-P. P., J. F.]; Centre Léon Bérard, Lyon, France [C. L.]; Hospices Civils de Lyon, Lyon, France [S. Gi., O. M. S.]; Centre Paul Strauss, Strasbourg, France [D. M., J-P. F.]; Centre François Baclesse, Caen, France [A. H., P. B.]; Centre René Gauducheau, Nantes, France [C. M.]; Centre René Huguenin, St. Cloud, France [C. N., R. L.]; Institut Bergonié, Bordeaux, France [M. L.]; Centre d’Etudes Polymorphisme des Humains, Paris, France [S. O.]; Institut Claudius Regaud, Toulouse, France [C. T., R. G.]; National Center for Scientific Research Demokritos, Athens, Greece [D. Y.]; Centre Hospitalo Universitaire Laval, Quebec, Canada [F. D., A-M. M., J. S.]; Consortium Interdisciplinary Health Research International Team on Breast Cancer Susceptibility (INHERIT BRCAs) [F. D., A-M. M., J. S.]; and Creighton University, Omaha, Nebraska [H. T. L.]

Strong inter- and intrafamilial variation of penetrance of breast and ovarian cancer is observed in BRCA1 mutation carriers. The wild-type copy of the BRCA1 gene is a plausible candidate as a cancer risk modifier given that the residual function corresponding to the intact BRCA1 allele may influence the process of tumor formation in BRCA1 carriers. Indeed, growing evidence is now becoming available on impaired reparation of double-strand DNA breaks in cells heterozygous for BRCA1 mutations, implying an enhanced mutability of BRCA1+/- cells. To determine whether certain variant forms of the wild-type BRCA1 allele are implicated in variation of the BRCA1-related cancer risk, their effect was studied in a panel of 591 women with BRCA1 germ-line mutations. We found that BRCA1 carriers with the wild-type BRCA1 copy bearing a common Gly1038 variant were at increased risk of ovarian cancer (hazards ratio, 1.50; 95% confidence interval, 1.03–2.19). The results of our study imply that a quite significant proportion of the interindividual variability in ovarian cancer penetrance in BRCA1 carriers may be explained by a common BRCA1 Gly1038 wild-type allele, given its high frequency (0.27).




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. J. Hughes, S. M. Ginolhac, I. Coupier, M. Corbex, B. Bressac-de-Paillerets, A. Chompret, Y.-J. Bignon, N. Uhrhammer, C. Lasset, S. Giraud, et al.
Common BRCA2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA1 Mutation Carriers
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 265 - 267.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.